
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio Inc. possesses significant potential in the pharmaceutical sector, particularly with its lead product, Buntanetap, aimed at modifying disease progression in chronic neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. The company has received positive interim results from its trials, indicating reduced sAPP levels, and is planning to initiate a Phase 2 trial in the second half of 2025, which could further validate its drug development efforts. Furthermore, Annovis Bio has established alignment with the FDA for a potential new drug application (NDA) contingent upon the success of its upcoming study designs, bolstering confidence in the prospects for future regulatory approvals and market entry.
Bears say
Annovis Bio Inc is facing significant financial challenges, including a limited cash runway that may necessitate dilutive capital raising activities. The company's pipeline, focused on difficult-to-treat neurodegenerative conditions like Alzheimer's and Parkinson's diseases, is associated with high risks of trial failures related to efficacy and safety, as well as potential setbacks in FDA approval processes. Additionally, the competition and pricing pressures in the pharmaceutical market pose threats to the successful launch and commercial performance of its products.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares